Free Trial
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free TSTL Stock Alerts

Tristel (TSTL) Competitors

Tristel logo
GBX 382.50 +10.00 (+2.68%)
As of 05/29/2026 12:28 PM Eastern
Compare

TSTL vs. AMS, SPEC, BVC, AKR, and ODX

Should you buy Tristel stock or one of its competitors? MarketBeat compares Tristel with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tristel include Advanced Medical Solutions Group (AMS), INSPECS Group (SPEC), BATM Advanced Communications (BVC), Akers Biosciences (AKR), and Omega Diagnostics Group (ODX). These companies are all part of the "medical instruments & supplies" industry.

How does Tristel compare to Advanced Medical Solutions Group?

Tristel (LON:TSTL) and Advanced Medical Solutions Group (LON:AMS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.7%. Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.2%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend.

Tristel has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.718, indicating that its stock price is 28% less volatile than the broader market.

Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.70£6.54M£16.2423.55
Advanced Medical Solutions Group£228.94M2.07£11.22M£4.5248.45

22.0% of Tristel shares are held by institutional investors. Comparatively, 22.6% of Advanced Medical Solutions Group shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Comparatively, 4.1% of Advanced Medical Solutions Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tristel has a net margin of 15.88% compared to Advanced Medical Solutions Group's net margin of 4.35%. Tristel's return on equity of 23.64% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
Advanced Medical Solutions Group 4.35%3.87%2.35%

In the previous week, Advanced Medical Solutions Group had 1 more articles in the media than Tristel. MarketBeat recorded 2 mentions for Advanced Medical Solutions Group and 1 mentions for Tristel. Advanced Medical Solutions Group's average media sentiment score of 0.91 beat Tristel's score of 0.00 indicating that Advanced Medical Solutions Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tristel
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Advanced Medical Solutions Group
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tristel currently has a consensus price target of GBX 400, suggesting a potential upside of 4.58%. Advanced Medical Solutions Group has a consensus price target of GBX 270.25, suggesting a potential upside of 23.40%. Given Advanced Medical Solutions Group's stronger consensus rating and higher probable upside, analysts clearly believe Advanced Medical Solutions Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Advanced Medical Solutions Group
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Advanced Medical Solutions Group beats Tristel on 11 of the 18 factors compared between the two stocks.

How does Tristel compare to INSPECS Group?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Tristel has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.674, indicating that its share price is 67% more volatile than the broader market.

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
INSPECS Group -2.67%-6.07%0.45%

In the previous week, Tristel had 1 more articles in the media than INSPECS Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for INSPECS Group. Tristel's average media sentiment score of 0.00 equaled INSPECS Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
INSPECS Group Neutral

22.0% of Tristel shares are owned by institutional investors. Comparatively, 14.8% of INSPECS Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 21.0% of INSPECS Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.70£6.54M£16.2423.55
INSPECS Group£191.70M0.45-£4.11M-£8.06N/A

Tristel presently has a consensus target price of GBX 400, suggesting a potential upside of 4.58%. INSPECS Group has a consensus target price of GBX 60, suggesting a potential downside of 29.41%. Given Tristel's higher possible upside, equities analysts plainly believe Tristel is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Tristel beats INSPECS Group on 11 of the 15 factors compared between the two stocks.

How does Tristel compare to BATM Advanced Communications?

Tristel (LON:TSTL) and BATM Advanced Communications (LON:BVC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Tristel currently has a consensus target price of GBX 400, suggesting a potential upside of 4.58%. Given Tristel's higher possible upside, equities research analysts clearly believe Tristel is more favorable than BATM Advanced Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
BATM Advanced Communications
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

22.0% of Tristel shares are owned by institutional investors. Comparatively, 16.9% of BATM Advanced Communications shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 30.4% of BATM Advanced Communications shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tristel has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, BATM Advanced Communications has a beta of 0.727, indicating that its share price is 27% less volatile than the broader market.

In the previous week, Tristel had 1 more articles in the media than BATM Advanced Communications. MarketBeat recorded 1 mentions for Tristel and 0 mentions for BATM Advanced Communications. Tristel's average media sentiment score of 0.00 equaled BATM Advanced Communications'average media sentiment score.

Company Overall Sentiment
Tristel Neutral
BATM Advanced Communications Neutral

Tristel has a net margin of 15.88% compared to BATM Advanced Communications' net margin of -14.90%. Tristel's return on equity of 23.64% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
BATM Advanced Communications -14.90%-22.13%0.58%

Tristel has higher earnings, but lower revenue than BATM Advanced Communications. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.70£6.54M£16.2423.55
BATM Advanced Communications£123.20M0.38-£278.26K-£4.20N/A

Summary

Tristel beats BATM Advanced Communications on 10 of the 15 factors compared between the two stocks.

How does Tristel compare to Akers Biosciences?

Tristel (LON:TSTL) and Akers Biosciences (LON:AKR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Tristel currently has a consensus price target of GBX 400, suggesting a potential upside of 4.58%. Given Tristel's stronger consensus rating and higher possible upside, equities research analysts plainly believe Tristel is more favorable than Akers Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Akers Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Tristel has higher revenue and earnings than Akers Biosciences. Akers Biosciences is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.70£6.54M£16.2423.55
Akers Biosciences£2.32M0.00N/A-£129.60N/A

22.0% of Tristel shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Tristel had 1 more articles in the media than Akers Biosciences. MarketBeat recorded 1 mentions for Tristel and 0 mentions for Akers Biosciences. Tristel's average media sentiment score of 0.00 equaled Akers Biosciences'average media sentiment score.

Company Overall Sentiment
Tristel Neutral
Akers Biosciences Neutral

Tristel has a net margin of 15.88% compared to Akers Biosciences' net margin of 0.00%. Tristel's return on equity of 23.64% beat Akers Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
Akers Biosciences N/A N/A N/A

Summary

Tristel beats Akers Biosciences on 11 of the 11 factors compared between the two stocks.

How does Tristel compare to Omega Diagnostics Group?

Tristel (LON:TSTL) and Omega Diagnostics Group (LON:ODX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Tristel had 1 more articles in the media than Omega Diagnostics Group. MarketBeat recorded 1 mentions for Tristel and 0 mentions for Omega Diagnostics Group. Tristel's average media sentiment score of 0.00 equaled Omega Diagnostics Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
Omega Diagnostics Group Neutral

Tristel has higher revenue and earnings than Omega Diagnostics Group. Omega Diagnostics Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.70£6.54M£16.2423.55
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A

Tristel has a net margin of 15.88% compared to Omega Diagnostics Group's net margin of -51.15%. Tristel's return on equity of 23.64% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
Omega Diagnostics Group -51.15%-29.14%-10.53%

22.0% of Tristel shares are owned by institutional investors. Comparatively, 29.8% of Omega Diagnostics Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Comparatively, 50.6% of Omega Diagnostics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tristel has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Omega Diagnostics Group has a beta of 3.85, indicating that its share price is 285% more volatile than the broader market.

Tristel presently has a consensus target price of GBX 400, indicating a potential upside of 4.58%. Given Tristel's stronger consensus rating and higher possible upside, equities research analysts plainly believe Tristel is more favorable than Omega Diagnostics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Omega Diagnostics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Tristel beats Omega Diagnostics Group on 10 of the 13 factors compared between the two stocks.

Get Tristel News Delivered to You Automatically

Sign up to receive the latest news and ratings for TSTL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TSTL vs. The Competition

Export
MetricTristelMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£183.34M£3.34B£5.82B£2.83B
Dividend Yield3.74%2.03%2.69%6.07%
P/E Ratio23.5516.3521.63365.74
Price / Sales3.7073.00590.9687,759.94
Price / Cash20.96146.5443.2227.89
Price / Book5.602.3810.557.79
Net Income£6.54M£99.80M£3.56B£5.89B
7 Day Performance0.66%1.04%2.85%0.82%
1 Month Performance-2.42%5.58%4.59%10.96%
1 Year Performance3.46%-8.04%37.62%78.69%

Tristel Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TSTL
Tristel
1.1527 of 5 stars		GBX 382.50
+2.7%		GBX 400
+4.6%		+3.5%£183.34M£49.54M23.55208
AMS
Advanced Medical Solutions Group
2.541 of 5 stars		GBX 218.50
+3.3%		GBX 270.25
+23.7%		+10.8%£473.96M£228.94M48.3410
SPEC
INSPECS Group
0.4904 of 5 stars		GBX 82
-1.8%		GBX 60
-26.8%		+62.2%£83.37M£191.70MN/A1,673
BVC
BATM Advanced Communications
N/AGBX 13.73
-0.1%		N/A-24.4%£46.70M£123.20MN/A980
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:TSTL) was last updated on 5/31/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel